Sulbenicillin |
|
| AHFS/Drugs.com | International Drug Names |
|---|
| ATC code | |
|---|
|
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenyl-2-sulfoacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
| ECHA InfoCard | 100.050.462 |
|---|
|
| Formula | C16H18N2O7S2 |
|---|
| Molar mass | 414.45 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](c3ccccc3)S(=O)(=O)O)C(=O)O)C
|
InChI=1S/C16H18N2O7S2/c1-16(2)11(15(21)22)18-13(20)9(14(18)26-16)17-12(19)10(27(23,24)25)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,17,19)(H,21,22)(H,23,24,25)/t9-,10-,11+,14-/m1/s1 NKey:JETQIUPBHQNHNZ-NJBDSQKTSA-N N
|
N Y (what is this?) (verify) |
Sulbenicillin (INN) is a penicillin antibiotic. It has been used in combination with dibekacin.[1]
References
Antibacterials active on the cell wall and envelope (J01C-J01D) |
|---|
β-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases) | | Penicillins (Penams) | Narrow spectrum | β-lactamase sensitive (1st generation) | |
|---|
β-lactamase resistant (2nd generation) | |
|---|
|
|---|
Extended spectrum | | Aminopenicillins (3rd generation) | |
|---|
| Carboxypenicillins (4th generation) | |
|---|
| Ureidopenicillins (4th generation) | |
|---|
| Other | |
|---|
|
|---|
|
|---|
| Carbapenems / Penems |
- Carbapenems (Ertapenem
- Antipseudomonal (Doripenem
- Imipenem
- Meropenem)
- Biapenem‡
- Panipenem)
- Penems (Faropenem
- Ritipenem§
- Sulopenem)
|
|---|
Cephems Cephalosporins Cephamycins Carbacephems | | 1st generation | |
|---|
| 2nd generation | |
|---|
| 3rd generation | |
|---|
| 4th generation |
- Cefepime
- Cefozopran‡
- Cefpirome
- Cefquinome‡
|
|---|
| 5th generation |
- Ceftaroline fosamil
- Ceftolozane
- Ceftobiprole
|
|---|
| Siderophore | |
|---|
| Veterinary |
- Ceftiofur
- Cefquinome
- Cefovecin
|
|---|
|
|---|
| Monobactams |
- Aztreonam
- Tigemonam‡
- Carumonam‡
- Nocardicin A‡
|
|---|
| β-lactamase inhibitors |
- Penam (Sulbactam
- Tazobactam
- Enmetazobactam)
- Clavam (Clavulanic acid)
- non-β-lactam (Avibactam
- Durlobactam
- Relebactam
- Taniborbactam
- Vaborbactam)
|
|---|
| Combinations |
- Amoxicillin/clavulanic acid#
- Ampicillin/flucloxacillin
- Ampicillin/sulbactam (Sultamicillin)
- Aztreonam/avibactam
- Benzathine benzylpenicillin/procaine benzylpenicillin
- Cefepime/enmetazobactam
- Cefepime/sulbactam
- Cefoperazone/sulbactam
- Ceftazidime/avibactam
- Ceftolozane/tazobactam
- Imipenem/cilastatin#
- Imipenem/cilastatin/relebactam
- Meropenem/vaborbactam
- Panipenem/betamipron
- Piperacillin/tazobactam
- Sulbactam/durlobactam
- Sulopenem/probenecid
- Ticarcillin/clavulanic acid
|
|---|
|
|---|
| Polypeptides | | Lipopeptides |
- Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
- Surfactin
|
|---|
| Other |
- Inhibits PG elongation and crosslinking: Ramoplanin§
|
|---|
|
|---|
| Intracellular |
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition
- DADAL/AR inhibitors
- bactoprenol inhibitors
|
|---|
| Other |
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|